| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | METTL1 |
| Uniprot No | Q9UBP6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-276aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMAAETRNVAGAEAPPPQKRYYRQRAHSNPM ADHTLRYPVKPEEMDWSELYPEFFAPLTQNQSHDDPKDKKEKRAQAQVEF ADIGCGYGGLLVELSPLFPDTLILGLEIRVKVSDYVQDRIRALRAAPAGG FQNIACLRSNAMKHLPNFFYKGQLTKMFFLFPDPHFKRTKHKWRIISPTL LAEYAYVLRVGGLVYTITDVLELHDWMCTHFEEHPLFERVPLEDLSEDPV VGHLGTSTEEGKKVLRNGGKNFPAIFRRIQDPVLQAVTSQTSLPGH |
| 预测分子量 | 34 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于METTL1重组蛋白的3篇代表性文献的简要概括(信息基于公开研究数据整理)：
---
1. **文献名称**：*Structural basis of regulated m7G tRNA modification by METTL1*
**作者**：Lin S. et al. (2021)
**摘要**：该研究解析了人源METTL1-WDR4复合物的晶体结构，阐明了其催化tRNA第7位鸟嘌呤甲基化(m7G)的分子机制，并通过重组蛋白验证了关键功能域对酶活性的调控作用。
---
2. **文献名称**：*METTL1 promotes let-7 microRNA processing via m7G methylation*
**作者**：Pandolfini L. et al. (2019)
**摘要**：研究发现METTL1通过介导m7G修饰调控let-7 miRNA的生物合成，利用重组METTL1蛋白进行体外实验，证明其甲基转移酶活性对miRNA成熟体的稳定性至关重要。
---
3. **文献名称**：*METTL1 drives tumor progression through m7G tRNA modification in colorectal cancer*
**作者**：Chen Z. et al. (2022)
**摘要**：通过体外重组METTL1蛋白功能实验，揭示METTL1通过增强致癌基因相关tRNA的翻译效率促进结直肠癌转移，为靶向METTL1的癌症治疗提供依据。
---
**备注**：如需具体文献DOI或补充更多研究，可进一步说明具体需求方向(如结构、疾病机制或方法学)。
The METTL1 (Methyltransferase 1) recombinant protein is a key focus in RNA modification research due to its role in catalyzing the transfer of methyl groups to RNA molecules. As a member of the 7-methylguanine (m7G) methyltransferase family, METTL1 primarily modifies transfer RNA (tRNA) at position 46 of the variable loop, a critical post-transcriptional modification that enhances tRNA stability, structural integrity, and translational efficiency. This enzyme forms a functional complex with its cofactor WD Repeat Domain 83 (WDR83), which aids in substrate recognition and catalytic activity.
Recombinant METTL1 protein is produced through heterologous expression systems (e.g., E. coli or mammalian cells) for biochemical and functional studies. Its production enables researchers to investigate the molecular mechanisms underlying m7G modifications and their broader implications in cellular processes. METTL1-mediated methylation has been linked to mRNA translation regulation, ribosome biogenesis, and stress response pathways. Dysregulation of METTL1 is associated with multiple diseases, including cancers (e.g., hepatocellular carcinoma, glioblastoma), neurodevelopmental disorders, and viral infections, where abnormal tRNA modification may promote oncogenic translation or viral replication.
Recent studies highlight METTL1's dual role as both a tumor promoter and suppressor, depending on cellular context, making it a potential therapeutic target. Structural analyses of recombinant METTL1-WDR83 complexes have revealed binding interfaces critical for enzymatic activity, informing drug discovery efforts. Challenges remain in understanding tissue-specific regulation of METTL1 and its cross-talk with other RNA modification pathways. As a research tool, recombinant METTL1 facilitates high-throughput screening for inhibitors and functional studies using CRISPR-engineered cell models, advancing precision medicine strategies targeting epitranscriptomic mechanisms.
×
